Options of immunotherapeutic treatments for children with asthma.

This article will discuss the available evidence on allergen immunotherapy and biologic drugs in pediatric asthma treatment. Expert opinion: Previously published studies demonstrated a good efficacy and safety profile of Allergen Immunotherapy in patients with mild-moderate asthma and sensitization to one main allergen. New understanding of mechanisms underlying severe asthma inflammation has allowed the identifications of specific biomarkers guiding the clinician in the choice of patient specific drug. Among the suggested immunotherapeutic options, omalizumab (blocking IgE) remains the first choice for atopic "early onset" asthma in patients aged over 6 years. Instead, mepolizumab (blocking the IL5 ligand) should be considered for "eosinophilic" asthma. Other biologic drugs are under consideration but data on the pediatric population are still lacking. PMID: 31414917 [PubMed - as supplied by publisher]
Source: Expert Review of Respiratory Medicine - Category: Respiratory Medicine Tags: Expert Rev Respir Med Source Type: research